Sudeep Pharma

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0QPI01025
  • NSEID: SUDEEPPHRM
  • BSEID: 544619
INR
847.00
-24.65 (-2.83%)
BSENSE

Jun 18

BSE+NSE Vol: 1.41 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

1.41 lacs (-62.71%) Volume

Shareholding (Mar 2026)

FII

1.55%

Held by 13 FIIs

DII

18.11%

Held by 18 DIIs

Promoter

76.15%

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Loading Valuation Snapshot...
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

INR 9,658 Cr ()

stock-summary
P/E

57.00

stock-summary
Industry P/E

34

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.00

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

11.15

Revenue and Profits:
Net Sales:
182 Cr
(Quarterly Results - Mar 2026)
Net Profit:
49 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
36.59%
0%
36.59%
6 Months
25.86%
0%
25.86%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%

Sudeep Pharma for the last several years.

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary

Announcement under Regulation 30 (LODR)-Earnings Call Transcript

28-May-2026 | Source : BSE

Submission of Earnings Call Transcript for Q4 FY26.

Compliances-Reg.24(A)-Annual Secretarial Compliance

27-May-2026 | Source : BSE

Submission of Annual Secretarial Compliance Report for FY 2025-26

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

23-May-2026 | Source : BSE

Pursuant to Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 as amended from time to time we herewith submit the participation of Company Officials in various Investor Conferences in Mumbai as annexed.

Corporate Actions stock-summary
stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

No Dividend history available

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
0
EBIT to Interest (avg)
33.98
Debt to EBITDA (avg)
0.72
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0.65
Tax Ratio
23.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
19.67%
ROCE (avg)
24.88%
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
57
Industry P/E
34
Price to Book Value
11.15
EV to EBIT
47.71
EV to EBITDA
44.53
EV to Capital Employed
10.75
EV to Sales
15.38
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
22.53%
ROE (Latest)
19.57%
Technicals key factors
Indicator
Weekly
Monthly
MACD
RSI
Bearish
Bollinger Bands
Bullish
KST
Dow Theory
Bullish
Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2026stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 14 Schemes (6.19%)

FIIs

Held by 13 FIIs (1.55%)

Promoter with highest holding

Riva Resources Private Limited (40.35%)

Highest Public shareholder

Nuvama Crossover Opportunities Fund - Series Iii (3.42%)

Individual Investors Holdings

3.11%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Standalone) - Mar'26 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025",
        "dir": -1
      },
      {
        "prefix": "Standalone Net Profit ",
        "suffix": "QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Dec'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "80.17",
          "val2": "90.28",
          "chgp": "-11.20%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "28.89",
          "val2": "29.61",
          "chgp": "-2.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "1.97",
          "val2": "0.63",
          "chgp": "212.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Standalone Net Profit",
          "val1": "25.77",
          "val2": "26.87",
          "chgp": "-4.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "36.04%",
          "val2": "32.80%",
          "chgp": "3.24%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "alert": "No Half Yearly Results declared by Sudeep Pharma"
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "alert": "No Nine Monthly Results declared by Sudeep Pharma"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'26",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'26",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "642.26",
          "val2": "502.00",
          "chgp": "27.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "221.91",
          "val2": "189.95",
          "chgp": "16.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "7.60",
          "val2": "5.85",
          "chgp": "29.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "172.89",
          "val2": "138.73",
          "chgp": "24.62%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "34.55%",
          "val2": "37.84%",
          "chgp": "-3.29%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Standalone) - Mar'26 - QoQstock-summary
Mar'26
Dec'25
Change(%)
Net Sales
80.17
90.28
-11.20%
Operating Profit (PBDIT) excl Other Income
28.89
29.61
-2.43%
Interest
1.97
0.63
212.70%
Exceptional Items
0.00
0.00
Standalone Net Profit
25.77
26.87
-4.09%
Operating Profit Margin (Excl OI)
36.04%
32.80%
3.24%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Mar 2026 is -11.20% vs 2.73% in Dec 2025

Direction Arrows
Standalone Net Profit

QoQ Growth in quarter ended Mar 2026 is -4.09% vs -9.65% in Dec 2025

Annual Results Snapshot (Consolidated) - Mar'26stock-summary
Mar'26
Mar'25
Change(%)
Net Sales
642.26
502.00
27.94%
Operating Profit (PBDIT) excl Other Income
221.91
189.95
16.83%
Interest
7.60
5.85
29.91%
Exceptional Items
0.00
0.00
Consolidate Net Profit
172.89
138.73
24.62%
Operating Profit Margin (Excl OI)
34.55%
37.84%
-3.29%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2026 is 27.94% vs 9.30% in Mar 2025

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2026 is 24.62% vs 4.16% in Mar 2025

stock-summaryCompany CV
About stock-summary
stock-summary
Company Coordinates stock-summary
Company Details
stock-summary
Tel:
stock-summary
stock-summary
Registrar Details